Business
Van Leeuwen Ice Cream Truck Los Angeles
(Getty Images)
in this econemy?

Van Leeuwen, America’s fastest-growing dessert chain, is looking to expand abroad

The boutique ice cream chain is looking to open at least 300 new shops in South Korea over the next decade.

What started as a small ice cream truck on the streets of New York City in 2008 has now evolved into a scoop empire with over 100 store locations across California, Texas, Colorado, and Florida — and Van Leeuwen is now beginning to look beyond the US. The company signed a rare franchise agreement to open at least 300 new ice cream shops in South Korea over the next decade, starting with five store openings in the new market for this year.

For the boutique scoop shop chain where ice cream lovers can choose from more than 100 flavors, including some eyebrow-raising limited-time specials like Kraft Macaroni & Cheese, expanding its footprint has become a top priority, per a recent Bloomberg interview with CEO and cofounder Ben Van Leeuwen.

Indeed, the company’s impressive expansion in its home country, having nearly quadrupled its store count in the four years up to 2025, is helping it scoop more revenue to add to its top line. In 2024, Van Leeuwen’s sales had grown 39% year on year to $65 million, per estimates from food service industry tracker Technomics, while the parlor chain also ranked as the fastest-growing dessert concept from the top 500 American restaurants tracked by Technomics last year.

It’s also found success tapping into retail channels like Walmart and Whole Foods, selling pints of its speciality ice cream to 12,000 grocery stores as of the end of last year — up from just 100 stores in 2018.

Sundae scaries

Zooming out, there might be another reason that Van Leeuwen is putting more stock in reaching new overseas markets, with a previously attempted experiment in Singapore and now in Korea: Americans might well be falling out of love with ice cream.

Per the US Department of Agriculture, per-capita ice cream consumption has been on a downward trend for decades, dropping 34% as of 2024 since the USDA started collecting data in 1975. South Korea, on the other hand, has seen domestic ice cream sales and imports rebound in recent years, according to the department’s Foreign Agricultural Service Report.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.